{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T10:52:48Z","timestamp":1774263168137,"version":"3.50.1"},"reference-count":45,"publisher":"FapUNIFESP (SciELO)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Assoc. Med. Bras."],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:p>Summary Introduction: Diabetes mellitus is one of the most common chronic diseases in the world, with high morbidity and mortality rates, resulting in a greatly negative socioeconomic impact. Although there are several classes of oral antidiabetic agents, most of the patients are outside the therapeutic goal range. Objective: To review the use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus, focusing on their favorable and unfavorable effects, as well as on cardiovascular profile. Method: A literature search on Pubmed database was performed using the following keywords: \"SGLT-2 inhibitors,\" \"dapagliflozin,\" \"empagliflozin,\" \"canagliflozin.\" Results: SGLT-2 inhibitors are a class of oral antidiabetic drugs directed to the kidney. Their mechanism of action is to reduce blood glucose by inducing glycosuria. Extra-glycemic benefits have been described, such as weight loss, decline in blood pressure and levels of triglycerides and uric acid, and they can slow the progression of kidney disease. Genitourinary infections are the main side effects. There is a low risk of hypotension and hypoglycemia. Diabetic ketoacidosis is a serious adverse effect, although rare. Empagliflozin has already had its cardiovascular benefit demonstrated and studies with other drugs are currently being performed. Conclusion: SGLT-2 inhibitors are a new treatment option for type 2 diabetes mellitus, acting independently of insulin. They have potential benefits other than the reduction of blood glucose, but also carry a risk for adverse effects.<\/jats:p>","DOI":"10.1590\/1806-9282.63.07.636","type":"journal-article","created":{"date-parts":[[2017,9,30]],"date-time":"2017-09-30T23:29:12Z","timestamp":1506814152000},"page":"636-641","source":"Crossref","is-referenced-by-count":15,"title":["Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus"],"prefix":"10.1590","volume":"63","author":[{"given":"Leyna Leite","family":"Santos","sequence":"first","affiliation":[{"name":"Centro de Estudos Superiores de Macei\u00f3, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando Jos\u00e9 Camello de","family":"Lima","sequence":"additional","affiliation":[{"name":"Universidade Federal de Alagoas, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9lio Fernando de","family":"Sousa-Rodrigues","sequence":"additional","affiliation":[{"name":"Ufal, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiano Timb\u00f3","family":"Barbosa","sequence":"additional","affiliation":[{"name":"Ufal, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"issue":"2","key":"ref1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diabres.2013.11.002","article-title":"Global estimates of the prevalence of diabetes for 2013 and projections for 2035 for the IDF Diabetes Atlas","volume":"103","author":"Guariguata L","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"ref2","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","article-title":"Global prevalence of diabetes: estimates for the year 2000 and projections for 2030","volume":"27","author":"Wild S","year":"2004","journal-title":"Diabetes Care"},{"issue":"1","key":"ref3","first-page":"S16","article-title":"Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin","volume":"20","author":"Bailey RA","year":"2014","journal-title":"Am J Manag Care"},{"issue":"4","key":"ref4","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"DeFronzo RA","year":"2009","journal-title":"Diabetes"},{"issue":"4","key":"ref5","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2337\/dc06-2170","article-title":"Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management","volume":"30","author":"Grant R","year":"2007","journal-title":"Diabetes Care"},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s13300-011-0004-1","article-title":"Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes","volume":"2","author":"Hardman TC","year":"2011","journal-title":"Diabetes Ther"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1681\/ASN.2010030246","article-title":"SGLT2 mediates glucose reabsorption in the early proximal tubule","volume":"22","author":"Vallon V","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"C14","DOI":"10.1152\/ajpcell.00388.2010","article-title":"Glucose transport by human renal Na+\/D-glucose cotransporters SGLT1 and SGLT2","volume":"300","author":"Hummel CS","year":"2011","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"F10","DOI":"10.1152\/ajprenal.2001.280.1.F10","article-title":"Renal Na(+)-glucose cotransporters","volume":"280","author":"Wright EM","year":"2001","journal-title":"Am J Physiol Renal Physiol"},{"issue":"10","key":"ref10","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"33","author":"Ferrannini E","year":"2010","journal-title":"Diabetes Care"},{"issue":"8","key":"ref11","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrendo.2011.243","article-title":"SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects","volume":"8","author":"Ferrannini E","year":"2012","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.diabres.2014.02.014","article-title":"SGLT2 inhibitors in the treatment of type 2 diabetes","volume":"104","author":"Hasan FM","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"issue":"120","key":"ref13","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1038\/ki.2010.512","article-title":"Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans","author":"List JF","year":"2011","journal-title":"Kidney Int Suppl"},{"issue":"8","key":"ref14","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/j.1742-1241.2008.01829.x","article-title":"Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes","volume":"62","author":"Jabbour SA","year":"2008","journal-title":"Int J Clin Pract"},{"issue":"8","key":"ref15","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.2337\/dc12-2391","article-title":"Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion results of a randomized, placebo-controlled study","volume":"36","author":"Polidori D","year":"2013","journal-title":"Diabetes Care"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1053\/j.ajkd.2008.12.031","article-title":"Glucose control by the kidney: an emerging target in diabetes","volume":"53","author":"Marsenic O","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"ref17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/dom.12244","article-title":"Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"16","author":"Monami M","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"ref18","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/dc08-1863","article-title":"Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes","volume":"32","author":"List JF","year":"2009","journal-title":"Diabetes Care"},{"issue":"9733","key":"ref19","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey CJ","year":"2010","journal-title":"Lancet"},{"issue":"9896","key":"ref20","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu WT","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"ref21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/dom.12189","article-title":"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin","volume":"16","author":"Bolinder J","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/med.20142","article-title":"Recent and emerging anti-diabetes targets","volume":"29","author":"Mohler ML","year":"2009","journal-title":"Med Res Rev"},{"issue":"4","key":"ref23","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jash.2014.01.007","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis","volume":"8","author":"Baker WL","year":"2014","journal-title":"J Am Soc Hypertens"},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou D","year":"2013","journal-title":"Ann Intern Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney DZ","year":"2014","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"ref26","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1161\/CIRCULATIONAHA.106.658948","article-title":"Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study","volume":"115","author":"Fox CS","year":"2007","journal-title":"Circulation"},{"issue":"3","key":"ref27","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S2213-8587(13)70088-3","article-title":"Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions","volume":"2","author":"Biessels GJ","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","article-title":"Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice","volume":"13","author":"Lin B","year":"2014","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"ref29","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1053\/j.ajkd.2008.12.021","article-title":"Uric acid and long term outcomes in CKD","volume":"53","author":"Madero M","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"ref30","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/dom.12439","article-title":"Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus","volume":"17","author":"Davies MJ","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"ref31","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1463-1326.2012.01569.x","article-title":"Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus","volume":"14","author":"Luippold G","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"ref32","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2337\/dc13-2955","article-title":"Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study","volume":"38","author":"Henry RR","year":"2015","journal-title":"Diabetes Care"},{"issue":"6","key":"ref33","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/13543784.2014.909407","article-title":"Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes","volume":"23","author":"Lamos EM","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"ref34","doi-asserted-by":"crossref","first-page":"F317","DOI":"10.1152\/ajprenal.00145.2014","article-title":"The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob\/ob type 2 diabetic mice with and without hypertension","volume":"307","author":"Gembardt F","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"issue":"5","key":"ref35","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney DZ","year":"2014","journal-title":"Circulation"},{"issue":"4","key":"ref36","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner C","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"ref37","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett AH","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"ref38","first-page":"923","article-title":"Euglycemic diabetic ketoacidosis and severe acute kidney injury secondary to off labell use of sodium glucose cotransporter-2 onhibitor in a type-1 diabetic patient","volume":"27","author":"Tahir H","year":"2015","journal-title":"J Ayub Med Coll Abbottabad"},{"issue":"4","key":"ref39","doi-asserted-by":"crossref","first-page":"532","DOI":"10.2337\/dc15-1995","article-title":"Diabetic ketoacidosis with canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with type 1 diabetes","volume":"39","author":"Peters AL","year":"2016","journal-title":"Diabetes Care"},{"issue":"1","key":"ref40","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1210\/jc.2015-1860","article-title":"Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor","volume":"101","author":"Bilezikian JP","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"ref41","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1080\/03007995.2016.1174841","article-title":"The effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus","volume":"32","author":"Alba M","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"ref42","series-title":"Guidance for industry diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes","year":"2008"},{"issue":"5","key":"ref43","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/j.semerg.2015.10.010","article-title":"La empagliflozina reduce la mortalidad cardiovascular en pacientes diab\u00e9ticos con eventos cardiovasculares previos","volume":"42","author":"Segui D\u00edaz M","year":"2015","journal-title":"SEMERGEN"},{"issue":"3","key":"ref44","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3810\/pgm.2013.05.2654","article-title":"Sodium-glucose co-transporter 2 inhibitors and the potential for cardiovascular risk reduction in patients with type 2 diabetes mellitus","volume":"125","author":"Guthrie RM","year":"2013","journal-title":"Postgrad Med"},{"issue":"22","key":"ref45","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ramb\/v63n7\/0104-4230-ramb-63-07-0636.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T04:35:32Z","timestamp":1570163732000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0104-42302017000700636&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0104-42302017000700636"],"URL":"https:\/\/doi.org\/10.1590\/1806-9282.63.07.636","relation":{},"ISSN":["0104-4230"],"issn-type":[{"value":"0104-4230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}